Switch theme
Sign up to access all valuation multiples
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
2018
9.4K+
LTM Revenue $4.5B
LTM EBITDA $885M
$10.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Elanco has a last 12-month revenue (LTM) of $4.5B and a last 12-month EBITDA of $885M.
In the most recent fiscal year, Elanco achieved revenue of $4.4B and an EBITDA of $1.4B.
Elanco expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Elanco valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.5B | XXX | $4.4B | XXX | XXX | XXX |
| Gross Profit | $2.5B | XXX | $2.4B | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $885M | XXX | $1.4B | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 31% | XXX | XXX | XXX |
| EBIT | $752M | XXX | $251M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $438M | XXX | $338M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $3.9B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Elanco's stock price is $13.
Elanco has current market cap of $6.7B, and EV of $10.6B.
See Elanco trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.6B | $6.7B | XXX | XXX | XXX | XXX | $0.88 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Elanco has market cap of $6.7B and EV of $10.6B.
Elanco's trades at 2.4x EV/Revenue multiple, and 7.6x EV/EBITDA.
Equity research analysts estimate Elanco's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Elanco has a P/E ratio of 15.2x.
See valuation multiples for Elanco and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.7B | XXX | $6.7B | XXX | XXX | XXX |
| EV (current) | $10.6B | XXX | $10.6B | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 12.0x | XXX | 7.6x | XXX | XXX | XXX |
| EV/EBIT | 14.1x | XXX | 42.2x | XXX | XXX | XXX |
| EV/Gross Profit | 4.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.2x | XXX | 19.7x | XXX | XXX | XXX |
| EV/FCF | 17.3x | XXX | 27.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialElanco's last 12 month revenue growth is 3%
Elanco's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Elanco's rule of 40 is -2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Elanco's rule of X is 28% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Elanco and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -2% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Elanco acquired XXX companies to date.
Last acquisition by Elanco was XXXXXXXX, XXXXX XXXXX XXXXXX . Elanco acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Elanco founded? | Elanco was founded in 2018. |
| Where is Elanco headquartered? | Elanco is headquartered in United States of America. |
| How many employees does Elanco have? | As of today, Elanco has 9.4K+ employees. |
| Who is the CEO of Elanco? | Elanco's CEO is Mr. Jeffrey N. Simmons. |
| Is Elanco publicy listed? | Yes, Elanco is a public company listed on NYS. |
| What is the stock symbol of Elanco? | Elanco trades under ELAN ticker. |
| When did Elanco go public? | Elanco went public in 2018. |
| Who are competitors of Elanco? | Similar companies to Elanco include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Elanco? | Elanco's current market cap is $6.7B |
| What is the current revenue of Elanco? | Elanco's last 12 months revenue is $4.5B. |
| What is the current revenue growth of Elanco? | Elanco revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Elanco? | Current revenue multiple of Elanco is 2.4x. |
| Is Elanco profitable? | Yes, Elanco is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Elanco? | Elanco's last 12 months EBITDA is $885M. |
| What is Elanco's EBITDA margin? | Elanco's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Elanco? | Current EBITDA multiple of Elanco is 12.0x. |
| What is the current FCF of Elanco? | Elanco's last 12 months FCF is $612M. |
| What is Elanco's FCF margin? | Elanco's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Elanco? | Current FCF multiple of Elanco is 17.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
